APEIRON Biologics’ APN01 selected for large-scale US trial in COVID-19

APEIRON ́s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS Further clinical study in preparation with inhalative drug delivery of APN01 to directly target respiratory tract and lung tissue Additional pre-clinical data show highly promising results with APN01 in various mutation variants Financing round planned to secure funding of further upcoming development...
May 19, 2021
View the Post